Use of non‐LDL‐C lipid‐lowering medications in patients with type 2 diabetes
Abstract Background A number of non‐low‐density lipoprotein cholesterol lipid abnormalities are associated with type 2 diabetes and insulin resistance, which may lead practitioners to use medications targeting these abnormal lipid fractions despite a lack of evidence or guideline recommendations. Me...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-07-01
|
| Series: | Endocrinology, Diabetes & Metabolism |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/edm2.126 |
| _version_ | 1819228241580261376 |
|---|---|
| author | Suzanne V. Arnold Kensey Gosch Nathan D. Wong Vittal Hejjaji Abhinav Goyal Lawrence A. Leiter Mikhail Kosiborod |
| author_facet | Suzanne V. Arnold Kensey Gosch Nathan D. Wong Vittal Hejjaji Abhinav Goyal Lawrence A. Leiter Mikhail Kosiborod |
| author_sort | Suzanne V. Arnold |
| collection | DOAJ |
| description | Abstract Background A number of non‐low‐density lipoprotein cholesterol lipid abnormalities are associated with type 2 diabetes and insulin resistance, which may lead practitioners to use medications targeting these abnormal lipid fractions despite a lack of evidence or guideline recommendations. Methods and Results Among 382 921 US patients with type 2 diabetes (69% with cardiovascular disease, 76% on a statin), 95 995 (26%) were on some nonstatin lipid‐lowering medication—19 265 (5%) on niacin, 32 919 (9%) on a fibrate and 69 513 (18%) on fish oil. Use of all three medications was stable over time and higher in patients with cardiovascular disease and with higher triglyceride levels, although even among patients with triglyceride levels <2.3 mmol/L, 6% were on a fibrate and 17% were on fish oil. Conclusion As clinical trials demonstrate little to no cardiovascular benefit from taking these medications, greater attention is needed to focus the use of lipid‐lowering medications to those with proven benefit. |
| first_indexed | 2024-12-23T10:54:09Z |
| format | Article |
| id | doaj.art-36961b74edeb467ab5b8ca57d658e47d |
| institution | Directory Open Access Journal |
| issn | 2398-9238 |
| language | English |
| last_indexed | 2024-12-23T10:54:09Z |
| publishDate | 2020-07-01 |
| publisher | Wiley |
| record_format | Article |
| series | Endocrinology, Diabetes & Metabolism |
| spelling | doaj.art-36961b74edeb467ab5b8ca57d658e47d2022-12-21T17:49:48ZengWileyEndocrinology, Diabetes & Metabolism2398-92382020-07-0133n/an/a10.1002/edm2.126Use of non‐LDL‐C lipid‐lowering medications in patients with type 2 diabetesSuzanne V. Arnold0Kensey Gosch1Nathan D. Wong2Vittal Hejjaji3Abhinav Goyal4Lawrence A. Leiter5Mikhail Kosiborod6Saint Luke's Mid America Heart Institute and University of Missouri‐Kansas City Kansas City MissouriSaint Luke's Mid America Heart Institute and University of Missouri‐Kansas City Kansas City MissouriIrvine School of Medicine University of California Irvine CaliforniaSaint Luke's Mid America Heart Institute and University of Missouri‐Kansas City Kansas City MissouriEmory University School of Medicine Atlanta GeorgiaLi Ka Shing Knowledge Institute St. Michael's Hospital University of Toronto Toronto Ontario CanadaSaint Luke's Mid America Heart Institute and University of Missouri‐Kansas City Kansas City MissouriAbstract Background A number of non‐low‐density lipoprotein cholesterol lipid abnormalities are associated with type 2 diabetes and insulin resistance, which may lead practitioners to use medications targeting these abnormal lipid fractions despite a lack of evidence or guideline recommendations. Methods and Results Among 382 921 US patients with type 2 diabetes (69% with cardiovascular disease, 76% on a statin), 95 995 (26%) were on some nonstatin lipid‐lowering medication—19 265 (5%) on niacin, 32 919 (9%) on a fibrate and 69 513 (18%) on fish oil. Use of all three medications was stable over time and higher in patients with cardiovascular disease and with higher triglyceride levels, although even among patients with triglyceride levels <2.3 mmol/L, 6% were on a fibrate and 17% were on fish oil. Conclusion As clinical trials demonstrate little to no cardiovascular benefit from taking these medications, greater attention is needed to focus the use of lipid‐lowering medications to those with proven benefit.https://doi.org/10.1002/edm2.126diabetes mellituslipidsquality of caretriglycerides |
| spellingShingle | Suzanne V. Arnold Kensey Gosch Nathan D. Wong Vittal Hejjaji Abhinav Goyal Lawrence A. Leiter Mikhail Kosiborod Use of non‐LDL‐C lipid‐lowering medications in patients with type 2 diabetes Endocrinology, Diabetes & Metabolism diabetes mellitus lipids quality of care triglycerides |
| title | Use of non‐LDL‐C lipid‐lowering medications in patients with type 2 diabetes |
| title_full | Use of non‐LDL‐C lipid‐lowering medications in patients with type 2 diabetes |
| title_fullStr | Use of non‐LDL‐C lipid‐lowering medications in patients with type 2 diabetes |
| title_full_unstemmed | Use of non‐LDL‐C lipid‐lowering medications in patients with type 2 diabetes |
| title_short | Use of non‐LDL‐C lipid‐lowering medications in patients with type 2 diabetes |
| title_sort | use of non ldl c lipid lowering medications in patients with type 2 diabetes |
| topic | diabetes mellitus lipids quality of care triglycerides |
| url | https://doi.org/10.1002/edm2.126 |
| work_keys_str_mv | AT suzannevarnold useofnonldlclipidloweringmedicationsinpatientswithtype2diabetes AT kenseygosch useofnonldlclipidloweringmedicationsinpatientswithtype2diabetes AT nathandwong useofnonldlclipidloweringmedicationsinpatientswithtype2diabetes AT vittalhejjaji useofnonldlclipidloweringmedicationsinpatientswithtype2diabetes AT abhinavgoyal useofnonldlclipidloweringmedicationsinpatientswithtype2diabetes AT lawrencealeiter useofnonldlclipidloweringmedicationsinpatientswithtype2diabetes AT mikhailkosiborod useofnonldlclipidloweringmedicationsinpatientswithtype2diabetes |